Brooks Laboratories Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Brooks Laboratories Ltd reported a 83.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 76.0%.
- Its expenses for the quarter were up by 88.8% QoQ and 77.6% YoY.
- The net profit increased 15.4% QoQ and increased 17.8% YoY.
- The earnings per share (EPS) of Brooks Laboratories Ltd declined at 1.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 38.55 | 20.99 | 21.90 | 83.7% | 76.0% |
Total Expenses | 37.82 | 20.03 | 21.29 | 88.8% | 77.6% |
Profit Before Tax | 0.72 | 0.96 | 0.60 | -25.0% | 20.0% |
Tax | 0.03 | 0.00 | 0.03 | - | 0.0% |
Profit After Tax | -4.57 | -3.96 | -3.88 | 15.4% | 17.8% |
Earnings Per Share | -1.80 | -1.50 | -1.50 | 20.0% | 20.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Brooks Laboratories Ltd is a company primarily engaged in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical products. Their product portfolio typically includes formulations, active pharmaceutical ingredients (APIs), and other related healthcare products. While specific recent major developments for Brooks Laboratories Ltd are not provided in the data, companies in this industry often engage in activities such as expanding their product lines, enhancing manufacturing capabilities, or exploring partnerships and collaborations to boost their market position.
Revenue
In the third quarter of FY25, Brooks Laboratories Ltd reported a total income of ₹38.55 crores. This represented a significant increase, both quarter-over-quarter (QoQ) and year-over-year (YoY), with growth rates of 83.7% and 76.0%, respectively. Compared to the previous quarter (Q2FY25), where the total income was ₹20.99 crores, and the same period in the previous fiscal year (Q3FY24), with a total income of ₹21.90 crores, this increase marks a notable rise in revenue generation for the company during this period.
Profitability
Despite the growth in total income, Brooks Laboratories Ltd experienced challenges in terms of profitability. The profit before tax for Q3FY25 was ₹0.72 crores, a decline of 25.0% from Q2FY25, which recorded a profit before tax of ₹0.96 crores. However, this figure still represented a 20.0% increase compared to Q3FY24, where the profit before tax was ₹0.60 crores. After accounting for taxes, the company reported a loss, with a profit after tax of -₹4.57 crores in Q3FY25, compared to -₹3.96 crores in Q2FY25 and -₹3.88 crores in Q3FY24. The earnings per share also reflected this trend, standing at -₹1.80 for Q3FY25, compared to -₹1.50 in both Q2FY25 and Q3FY24, indicating a 20.0% increase in the loss per share QoQ and YoY.
Operating Metrics
The total expenses for Brooks Laboratories Ltd in Q3FY25 amounted to ₹37.82 crores, reflecting an increase of 88.8% QoQ from the ₹20.03 crores recorded in Q2FY25 and a 77.6% increase YoY from the ₹21.29 crores in Q3FY24. This increase in expenses, in tandem with the rise in total income, suggests a scaling up of operations or other cost-intensive activities during the period. Despite the increased income, the significant rise in expenses contributed to the company's negative profitability in Q3FY25, emphasizing operational challenges in maintaining cost efficiency relative to its income growth.
